Related Experiment Video
Updated: May 29, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
[The immune system and Alzheimer's disease]
E van Exel1, P Eikelenboom, H C Comijs
1VUMC/ GGZ inGeest, Amsterdam. e.vexel@vumc.nl
Tijdschrift Voor Psychiatrie
|September 8, 2011
Summary
Offspring with a family history of Alzheimer's disease (AD) show early signs of vascular risk factors and inflammation, suggesting a causal link. Early screening and treatment for hypertension can help prevent AD.
Area of Science:
- Neuroscience
- Genetics
- Cardiovascular Medicine
Context:
- The causal relationship between vascular risk factors, inflammation, and Alzheimer's disease (AD) remains unclear.
- Heredity's role in predisposing individuals to vascular risk factors and inflammatory responses in AD is under investigation.
Purpose:
- To investigate if offspring of parents with AD exhibit increased vascular risk factors and inflammatory responses compared to controls.
- To determine if genetic predisposition (APOE genotype) influences these risk factors and inflammatory markers.
Summary:
- Offspring of parents with AD had a higher prevalence of the APOE epsilon4 allele (47% vs. 21%).
- Middle-aged offspring of parents with AD displayed elevated blood pressure, greater atherosclerotic burden, and heightened pro-inflammatory cytokine responses.
- These findings suggest inherited pro-inflammatory profiles and hypertension are early risk factors for AD.
Impact:
- Identifies hypertension and inherited inflammatory profiles as critical early risk factors for late-onset AD.
- Recommends screening and proactive management of hypertension in individuals with a parental history of AD to mitigate AD development.
- Highlights the importance of genetic and inflammatory markers in predicting AD risk.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:40Cell-mediated Immune Responses
Overview
01:38What is the Immune System?
Overview
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...